Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
Rhea-AI Summary
Protalix BioTherapeutics (NYSE American: PLX) will release first quarter 2026 financial results and provide a business update on May 13, 2026. Management will host a conference call and live webcast at 8:00 a.m. EDT, with replay available for two weeks on the company investor website.
Investors should register 15 minutes early; call and webcast access details and Conference ID 13760475 are provided.
Positive
- None.
Negative
- None.
News Market Reaction – PLX
In the May 6 session, PLX gained 3.06%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 11 | Earnings date notice | Neutral | -0.3% | Announcement of date and time for fiscal 2025 results and business update. |
| Nov 06 | Earnings date notice | Neutral | -6.7% | Scheduling third-quarter 2025 results release and related conference call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-date announcements have historically coincided with modestly negative moves, with an average move of -3.53% across prior similar releases.
Over the last six months, Protalix has combined commercial progress with regulatory and pipeline updates. Fiscal 2025 results on Mar 18, 2026 highlighted revenue near prior-year levels, an EC approval for an Elfabrio every‑four‑weeks regimen, and a $25 million milestone expectation. Earlier, a stockholder letter on Jan 5, 2026 emphasized PRX‑115 clinical advancement and rare renal focus. The upcoming Q1 2026 earnings date continues a pattern of regular financial updates following these milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host conference call and webcast at 8:00 a.m. EDT
CARMIEL,
Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.
Conference Call Details:
Date: Wednesday, May 13, 2026
Time: 8:00 a.m. Eastern Daylight Time (EDT)
Toll Free: 1-877-423-9813
International: 1-201-689-8573
Israeli Toll Free: 1-809-406-247
Conference ID: 13760475
Call me™: https://tinyurl.com/yjww2vxn
The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
Webcast Details:
The conference will be webcast live from the Protalix website and will be available via the following links:
Company Link: https://ir.protalix.com/news-events/events
Webcast Link: https://tinyurl.com/ykmy9jmr
Conference ID: 13760475
Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website at the above link.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are currently available in multiple markets. These therapies are recombinant therapeutic proteins expressed through Protalix's proprietary plant cell-based expression system, ProCellEx®. ProCellEx is a unique plant cell-based system that enables Protalix to produce recombinant proteins in an industrial-scale manner with no exposure to mammalian cells. Protalix is the first company to gain
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio® which was approved by both the FDA and the European Medicines Agency (EMA) in May 2023. Protalix's development pipeline includes, among others, two proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; and PRX–119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases. To learn more, please visit www.protalix.com.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-first-quarter-2026-financial-results-and-business-update-on-may-13-2026-302763976.html
SOURCE Protalix BioTherapeutics, Inc.